A new num­ber 1 drug? Keytru­da tapped to top the 10 biggest block­busters on the world stage by 2024

An­a­lysts may be fret­ting about Keytru­da’s longterm prospects as a host of ri­val ther­a­pies el­bow their way to the mar­ket. But the folks at Eval­u­ate Phar­ma are con­fi­dent that last year’s $7 bil­lion earn­er is head­ed for glo­ry, tap­ping it to beat out the cur­rent #1 ther­a­py Hu­mi­ra as Ab­b­Vie watch­es that fran­chise swoon over the next 5 years.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER